phorbol-13-decanoate | 123597-59-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: phorbol-13-decanoate
• 英文别名: [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] decanoate
• CAS: 123597-59-1
• 化学式: C₃₀H₄₆O₇
• 分子量: 518.691
• InChiKey: YJFFPVQHOKPCRV-LKSXOGJWSA-N

物化性质

• 沸点：
  653.9±55.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  37
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  在 高氯酸 作用下， 以 甲醇 为溶剂， 生成 phorbol-13-decanoate
  参考文献：
  名称：

  Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation

  摘要：

  The persistence of latent reservoirs of HIV-1 represents a major barrier to virus eradication in patients treated with antiretrovirals. Prostratin is a non-tumor promoting 12-deoxyphorbol monoester capable of up-regulating viral expression from latent provirus and therefore is potentially useful for HIV adjuvant therapy and similar properties might be elicited by related non-tumor promoting phorboids. We have therefore investigated a series of phorbol 13-monoesters for their capacity to reactivate HIV latency. Using a Jurkat T cell line containing latent HIV proviruses, we found that prostratin and phorbol-13-stearate effectively activate HIV-1 gene expression in these latently infected cells, with phorbol-13-stearate being at least 10-fold more potent than prostratin, and its activity rapidly decreasing with a shortening of the acyl side chain. We further demonstrated that phorbol-13-stearate and prostratin stimulate IKK-dependent phosphorylation and degradation of I kappa B alpha, leading to activation of NF-kappa B. Moreover, prostratin, phorbol-13-hexanoate and phorbol-13-stearate also activate the JNK and ERK pathways. Studies with isoform-specific PKC inhibitors suggest that the classical PKCs play a prominent role in the responses elicited by phorbol-13-stearate. Nevertheless, this compound induces a translocation pattern of the PKC isotypes alpha and delta to cellular compartments distinctly different from that elicited by prostratin and PMA. (c) 2007 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bcp.2007.12.004

文献信息

• Multifunctional stealth nanoparticles for biomedical use
  申请人：Centre National de la Recherche Scientifique

  公开号：EP2210616A1

  公开（公告）日：2010-07-28

  The present invention relates to the field of drug delivery nanosystems. More precisely, the present invention concerns a copolymer with advantageous properties for the outer coating of various nanoparticles. Said copolymer comprises at least three types of monomers with stealthy, coupling and therapeutic properties respectively, as well as an optional fourth type of monomers with targeting properties. The present invention also relates to core-shell or hollow shell nanoparticles coated by an external layer of the copolymer according to the invention. Several types of core-shell nanoparticles are envisaged. The invention also concerns methods for preparing said nanoparticles, as well as pharmaceutical compositions or medicaments comprising them.

  本发明涉及给药纳米系统领域。更确切地说，本发明涉及一种具有优势特性的共聚物，可用于各种纳米粒子的外涂层。所述共聚物包括至少三种分别具有隐形、耦合和治疗特性的单体，以及可选的第四种具有靶向特性的单体。本发明还涉及由本发明共聚物外层包覆的核壳或空壳纳米粒子。本发明设想了多种类型的核壳纳米粒子。本发明还涉及制备上述纳米粒子的方法，以及包含这些纳米粒子的药物组合物或药物。
• Compositions and methods of use of phorbolesters
  申请人：Biosuccess Biotech Company

  公开号：EP2368555A1

  公开（公告）日：2011-09-28

  Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Thl cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseasesl. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols, therapeutic agents used to treat opportunistic infections due to HIV, or chemotherapeutic agents to yield more effective treatment tools against cytopathic diseases in mammalian subjects.

  本发明提供了含有植物醇酯或植物醇酯衍生物的方法和组合物，用于治疗细胞病理疾病。细胞病理疾病可由多种途径引起，如艾滋病毒和艾滋病等病毒感染，或哺乳动物体内肿瘤的发展。本发明的方法和组合物对于抑制新的 HIV 感染、上调潜伏前病毒的病毒表达、抑制 HIV 诱导的细胞病理效应、下调 HIV 受体、增加 Thl 细胞因子表达、减少 Th2 细胞因子表达、增加 ERK 磷酸化、诱导恶性细胞凋亡、诱导缓解、维持缓解、作为化疗药物以及减少细胞病理疾病症状和可能伴随此类疾病的机会性感染l 均有效。本研究还提供了其他组合物和方法，这些组合物和方法采用了一种抗坏血酸酯或衍生物化合物与至少一种额外的制剂结合使用，如HAART方案中使用的制剂、用于治疗HIV引起的机会性感染的治疗制剂或化疗制剂，以产生针对哺乳动物体内细胞病理疾病的更有效的治疗工具。
• Compositions and methods of use of phorbol esters for the treatment of stroke
  申请人：Biosuccess Biotech Co. Ltd.

  公开号：US10010519B2

  公开（公告）日：2018-07-03

  Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

  本发明提供了含有植物醇酯或植物醇酯衍生物的方法和组合物，用于治疗和预防中风及中风后遗症。此外，还提供了其他组合物和方法，这些组合物和方法采用了与至少一种额外制剂相结合的植物醇酯或衍生物化合物，以产生更有效的治疗工具来治疗或预防哺乳动物中风和中风的长期后遗症。
• Compositions and methods of use of phorbol esters in the treatment of neoplasms
  申请人：Biosuccess Biotech Co. Ltd.

  公开号：US10099996B2

  公开（公告）日：2018-10-16

  Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

  本发明提供了含有植物醇酯或植物醇酯衍生物的方法和组合物，用于治疗慢性和急性疾病。这些病症可能由疾病引起，也可能是疾病的症状、治疗方法或后遗症。所述的植物醇酯特别适用于治疗肿瘤性疾病和/或控制肿瘤性疾病化疗和放疗的副作用。
• Compositions and methods of use of phorbol esters
  申请人：Biosuccess Biotech Co., Ltd.

  公开号：US10258592B2

  公开（公告）日：2019-04-16

  Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

  本发明提供了含有植物醇酯或植物醇酯衍生物的方法和组合物，用于治疗慢性和急性疾病。这些病症可能由疾病引起，也可能是疾病的症状或后遗症。慢性和急性病症可能是由于病毒感染（如艾滋病毒和艾滋病）、肿瘤性疾病、中风、肾病、尿失禁、自身免疫性疾病、帕金森病、前列腺肥大、衰老或治疗此类疾病引起的。本研究还提供了其他组合物和方法，这些组合物和方法采用了一种磷酸酯或衍生物化合物，并与至少一种额外的制剂结合使用，以产生更有效的治疗工具，对抗哺乳动物体内的急性和慢性疾病。